Dr. Fertrin on the Potential of Fostamatinib in Chronic ITP

Video

Kleber Y. Fertrin, MD, PhD, assistant professor, University of Washington School of Medicine, and hematology oncologist, Seattle Cancer Care Alliance, discusses the potential of fostamatinib (Tavalisse) in the treatment of patients with chronic immune thrombocytopenia (ITP).

Kleber Y. Fertrin, MD, PhD, assistant professor, University of Washington School of Medicine, and hematology oncologist, Seattle Cancer Care Alliance, discusses the potential of fostamatinib (Tavalisse) in the treatment of patients with chronic immune thrombocytopenia (ITP).

Fostamatinib is the first Syk inhibitor that was developed for the treatment of patients with chronic ITP. The agent was approved by the FDA in 2018 for use as a second-line therapy in patients with chronic ITP following an insufficient response to prior therapy. The approval was based on findings from 2 randomized trials and 1 open-label extension study. Notably, the agent has shown a response rate of approximately 30% in patients who are refractory to 2, or potentially 3, prior therapies.

However, many questions remain with the agent, explains Fertrin, such as whether or not the agent can be combined with other therapies. Additionally, although the agent has shown activity in a heavily pretreated population, it is unclear whether it will possess the same activity in earlier lines of treatment, says Fertrin. Many clinical trials with fostamatinib in heavily pretreated and treatment-naïve patients with chronic ITP are anticipated.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS